Upload
herbert-riley
View
219
Download
0
Tags:
Embed Size (px)
Citation preview
Alcohol Interventions : Successful and Innovative Intervention
Strategies
John B Saunders MD, FRACP
Professor of Alcohol and Drug Studies, University of Queensland,
Director, Alcohol and Drug Service, Royal Brisbane
and Women’s Hospital, Queensland Health,
Co-Director, WHO Collaborating Centre on Substance Misuse and Mental Health; Member, Australian National Council on Drugs
ADTRU
The Spectrum of Use and Misuse
The Spectrum of Use and Misuse
Dependence
Hazardous/HarmfulUse/SubstanceAbuse
Non-Hazardous Use
Non-use
ADTRU
The Development of Substance Use Disorders
Repeated use of:• alcohol• certain medications• drugs
Development of a repetitive behaviour
Hazardous / Harmful Use/ Substance
Abuse
ADTRU
Mechanisms of Substance Dependence
Repeated use of:• alcohol• certain medications• drugs
Re-setting of dopamine reward
centres
Substance
dependence
syndrome
ADTRU
Alcohol’s Effects on Opioid Neurotransmission
Opioid (eg β endorphin)
neurone
Dopaminergic neurone
Nucleus accumbens
Ventral tegmental
area
GABA Neurone
ADTRU
The Dependence SyndromeThe Dependence SyndromeA psychobiological syndrome - a powerful internal
driving force. Features of the dependence syndrome:• impaired control over substance use• a strong desire to take the particular substance• preoccupation with substance use (given greater
priority than other activities)• increased tolerance• withdrawal symptoms on cessation of substance
use, or relief of withdrawal symptoms by further use
• continuation of use despite harmful effects
ADTRU
Dependence and the Reinstatement Phenomenon
Dependence and the Reinstatement Phenomenon
Implications
If a person is physically dependent on alcohol to the extent that they
repeatedly (>twice per week) suffer withdrawal symptoms, he/she is
best advised to abstain rather than attempt moderated or controlled
drinking.
A FEW DAYSALCOHOL
INTAKE
AND
SEVERITY
OF
DEPENDENCE
}}TIME
5 - 10 YEARS
ADTRU
Responses to Substance MisuseResponses to Substance Misuse
Tertiary
interventionBrief intervention
(Secondary prevention)
Primary prevention
ADTRU
Rapid Assessment
ADTRU
Audit
No 2 Yes, but not in the last year
4 Yes, during the last year
10. Has a relative, a friend, a doctor or another health worker been concerned about your drinking or suggested you cut down? 0 No 2 Yes, but not in the
last year4 Yes, during the last year
Select from the answers below and place the number that corresponds with your answer in the box
1. How often do you have a drink containing alcohol? Score
0 Never 1 or less 2 2 to 4 times a month
3 2 to 3 times a week
4 4 or more times a week
2. How many standard drinks do you have on a typical day when you are drinking? 0 1 or 2 1 2 to 4 2 5 or 6 3 7, 8 or 9 4 10 or more
3. How often do you have six or more drinks in one occasion? 0 Never 1 Less than monthly 2 Monthly 3 Weekly 4 Daily or almost daily
4. How often during the last year have you found that you were not able to stop drinking once you had started? 0 Never 1 Less than monthly 2 Monthly 3 Weekly 4 Daily or almost daily
5. How often during the last year have you failed to do what was normally expected from you because of drinking? 0 Never 1 Less than monthly 2 Monthly 3 Weekly 4 Daily or almost daily
6. How often during the last year have you needed a first drink in the morning to get yourself going after a heavy drinking session?
0 Never 1 Less than monthly 2 Monthly 3 Weekly 4 Daily or almost daily
7. How often during the last year have you had a feeling of guilt or remorse after drinking? 0 Never 1 Less than monthly 2 Monthly 3 Weekly 4 Daily or almost daily
8. How often during the lst year have you been unable to remember what happened the night before because you had been drinking?
0 Never 1 Less than monthly 2 Monthly 3 Weekly 4 Daily or almost daily
9. Have you or someone else been injured as a result of your drinking? 0
RECORD TOTAL OF SPECIFIC ITEMS HERE
ADTRU
Interpretation of the AUDIT Score
0 Abstainer
1-7 Non-hazardous
“safe” drinking
8-12 Hazardous or
harmful alcohol use
13+ High risk of alcohol dependence
ADTRU
Decision Tree
Offer AUDIT questionnaire
Review AUDIT score
Non-hazardous
range
Hazardous or
harmful range
Alcohol dependent
range
• Feedback, or no further action
• Feedback
• Brief intervention
• Feedback• Referral to specialist• Need for detoxification?• Pharmacotherapy
ADTRU
Brief Alcohol Intervention
ADTRU
• A brief and flexible form of therapy, comprising advice to reduce hazardous alcohol consumption and brief strategies to achieve this
• Ranges from 4 - 5 minutes to 2 - 3 sessions of up to 30 - 60 minutes
• Appropriate for people with hazardous alcohol use and a range of common mental health disorders
• Can complement other treatments for people who have an alcohol dependence syndrome
What is Brief Alcohol Intervention?
ADTRU
• Advice is usually to reduce drinking, rather than abstinence
• Aims to prevent exacerbation of drinking and alcohol-related harm and progression to dependence
• Can complement the treatment of alcohol dependence but is not appropriate as the sole treatment
Aims of Brief Alcohol Intervention
ADTRU
WHO Brief Intervention Study - findings from Australian Centre I
Aim: To determine the effectiveness of three types of brief intervention to assist persons with hazardous or harmful alcohol consumption reduce their intake and risk of harm
Design: Controlled clinical trial with random assignment to:
(1) No treatment control
(2) Simple advice (5 minutes and leaflet)
(3) Advice and brief counselling (20 minutes + manual)
(4) Advice and extended counselling (40 minutes over 2 - 3 sessions)
Saunders et al (1998)
ADTRU
Subjects: Males and females aged 17 - 70 years, fulfilling mean intake or binge drinking criteria
Settings: General practice, general outpatient clinics, health screening programs
Follow Up: at 9 months, 2 years and 10 years
Measures: Average weekly alcohol intake, frequency of drinking to intoxication, occurrence of hazardous drinking, alcohol-related problems score, laboratory test results
Evaluation: By repeated measures analysis of variance and regression modelling
WHO Brief Intervention Study - findings from Australian Centre II
Saunders et al (1998)
ADTRU
WHO - RPAH Early Intervention TrialResults at nine months
Average weekly alcohol intake (grams)
Condition Intake at Intake at % reduction
Recruitment Follow up
Control 402 402 0
Simple advice 424 307 27.5
Advice and 480 341 29.0counselling
Extended 460 285 38.0counselling
ADTRU
Aggregate Effect Sizes for Brief Intervention versus Control in Non-Treatment-Seeking
Populations
1. Composite Outcome
Follow-upperiod
No. ofStudies
Effect Size Heterogeneity (Q)
< 3 months 4 0.30* 4.5
3 – 6 months 11 0.14* 10.6
6 – 12 months 23 0.24* 30.6
> 12 months 5 0.13# 7.4
* P < 0.01 # P = 0.05 Moyer et al (2002)
ADTRU
Conclusions for Meta-analyses
• Brief interventions lead to a reduction in hazardous alcohol use, alcohol-related problems and biochemical abnormalities for at least 12 months
• No differential response according to gender or age
ADTRU
Four-year Outcome after Brief Intervention
Fleming et al (2002)
Treatment Control
Medical use (48-months postbaseline) Emergency department visits Days of hospitalization
(n = 392)302*420**
(n = 382)376*664**
Motor vehicle events (48-months postbaseline) Motor vehicle crash with fatality Motor vehicle crash with non-fatal injuries Motor vehicle crash with property damage only Operating while intoxicated Other moving violations
0 20 67 25169
2 31 72 25177
Legal events (48-months postbaseline) Assault/Battery/Child abuse Resist/Obstruct officer/Disorderly conduct Controlled substance/Liquor violation Criminal damage/Property damage Theft/Robbery Other arrests
8 8 2** 2 3 6
11 6 11** 1 3 9
* p < 0.10** p < 0.05
ADTRU
Drink-less: getting started
The Drink-less Program -how it works
Screening
– Receptionist gives AUDIT questionnaire to patient
– Patient brings questionnaire to consultation
ADTRU
ADTRU
ADTRU
ADTRU
NSW Alcohol Interlock Program• Voluntary means of reducing a lengthy
disqualification• Combines brief alcohol intervention and fitting
an interlock device to the motor vehicle• Operates on a ‘user pays’ basis • Interlock Driver Licence holders are subject to a
BAC < 0.02 • Failure to comply with requirements of Program
results in loss of licence
ADTRU
ADTRU
The Treatment of Alcohol Dependence
ADTRU
Alcohol Withdrawal
SYNDROME TIME OF ONSET DURATION
Simple 6 - 48 hours 24 hours - 5 days
Complicated 4 - 48 hours Usually singleby fits
Delirium Tremens 48 hours - 7 days 3 - 10 days
ADTRU
6 am 12 md 6 pm 12 mn
Day 1 10 mg 10 mg 10 mg 10 mg
Day 2 10 mg 10 mg 10 mg 10 mg
Day 3 5 mg 5 mg 5 mg 10 mg
Day 4 5 mg 5 mg 5 mg 10 mg
Day 5 Nil 5 mg Nil 5 mg
Alcohol 2 Protocol - Regular Diazepam
ADTRU
Pharmacotherapies for Alcohol Dependence
• Acamprosate (Campral)• Naltrexone (Revia)• Disulfiram (Antabuse)• Topiramate• Ondansetron• Buspirone (for alcohol dependence and
comorbid social anxiety)• SSRIs (for underlying or residual depression)
ADTRU
• A derivative of the amino-acid, taurine. Chemically calcium bis acetyl homotaurine
• Complex pharmacological actions
• Interacts with the GABAA receptor, facilitating GABAergic inhibitory neurotransmission
• Inhibits glutamate excitatory neurotransmission by interacting with NMDA glutamate receptor
AcamprosateAcamprosate
ADTRU
Alcohol’s Actions on Glutamate
Neurotransmission
ADTRU
Authors Country No. Duration Outcome
Abstinence % abstinent days Biochemistry
Paille et al. (1995 ) France 538 1 year A: 61% Biological markers
C: 47% showed greater
improvement in acamprosate group
Sass et al. (1997) Germany 272 1 year A: 43% 62%
C: 21% 45%
Tempesta et al. (1998) Italy 330 6 months A: 58% 66% No difference
C: 45% 54%
Besson et al. (1998) Switzerland 110 1 year A: 25% 40%
C: 5% 21%
Ritson,Chick et al. U.K. 581 6 months A: 12% No difference
(1999) C: 11%
Controlled trials of Acamprosate in Alcohol
Dependence. II
ADTRU
Naltrexone
• A specific antagonist of opioids
• Introduced in Australia in 1999 for the treatment of alcohol dependence
ADTRU
Alcohol’s Effects on Opioid Neurotransmission
Opioid (eg ß endorphin)
neurone
Dopaminergic neurone
Nucleus accumbens
Ventral tegmental
area
GABA Neurone
ADTRU
Controlled Trials of Naltrexone in Alcohol
Dependence. IAuthors Country No. Duration Outcome
Abstinence Relapse free Biochemistry
O’Malley et al. (1992 ) USA 104 3 months N: 51% 69%
C: 23% 40%
Volpicelli et al. (1992) USA 70 3 months N: 77% 79%
C: 46% 59%
Chick et al. (1999) UK 175 3 months N: 18%
C: 19%
Anton et al. (1999) USA 131 3 months N: 62% % with heavy
C: 40% drinking days less
in those on naltrexone
Morris et al. (2001) Australia 111 3 months N: 51% Improvement in those
C: 25% on naltrexone
ADTRU
Combined Pharmacotherapies for Alcohol Dependence. I :
Naltrexone and AcamprosateKiefer et al (2003) Study• Randomised, controlled trial of 160 alcohol dependent patients• Assigned, following detoxification, to one of four treatments
– placebo drug– naltrexone – acamprosate – naltrexone + acamprosate
• In addition, participants were encouraged to attend group therapy in a clinic setting
• Follow up at weekly intervals for three months
ADTRU
Results of Kiefer et al (2003) Study
As judged by time to first drink and time to relapse, • Naltrexone was superior to placebo• Acamprosate was superior to placebo• Combination of naltrexone and acamprosate was
superior to acamprosate alone• There was a trend for of naltrexone and acamprosate
combined to be superior to naltrexone alone
Combined Pharmacotherapies for Alcohol Dependence. I :
Naltrexone and Acamprosate
ADTRU
Alcohol-sensitising Drugs
• Aldehyde dehydrogenase inhibitors
Examples - disulfiram (“Antabuse”) 250 - 500mg daily• Result in an unpleasant flush reaction when alcohol is taken• Indications:
- alcohol dependence
- accepts goal of abstinence
- need for external aid to abstinence
- high risk situations for drinking imminent• Controlled trials indicate the abstinence rate is higher in the first
3-6 months when patients take these drugs• Best results are when given under supervision with contingency
management strategies
ADTRU
Topiramate in the Treatment of Alcohol Dependence
• Inhibits glutamate hypersensitivity and facilitates GABAergic function
• 150 patients assigned to either topiramate or placebo
• Greater reduction in quantity and intensity of alcohol consumption compared with placebo
• Reduction in GGT in topiramate-treated group compared with placebo Johnson
et al., 2003
ADTRU
Ondansetron• Early indications that ondansetron may be a
useful treatment for early-onset alcohol dependence (likely to be those with a positive family history)
• No support for its use in later onset alcohol dependence
• More evidence needed from controlled trials
• Not approved for the treatment of alcohol dependence in Australia
ADTRU
BuspironeBuspirone
• A 5HTIA partial agonist
• An anti-anxiety drug
• Shown in some small-scale trials to increase cumulative days of abstinence in people with alcohol dependence and comorbid social anxiety compared with placebo
ADTRU
SSRIs• Trialled (with high hopes) in the 1980s
• Reduce alcohol consumption by 20% in low dependence drinkers, but effect wears off after 1-2 months
• Do not increase abstinence rates in alcohol dependent people
• No change in overall alcohol intake in alcohol dependent people
• Reserved for patients with persistent depression after detoxification
ADTRU
Treatments for Alcohol MisuseBest practice Bad practice Available
Brief interventions Just say no!
CBT (limited)
MET (limited)
12 -step approaches 12-step approaches
Acamprosate (limited, if at all)
Naltrexone (limited)
Analytic psychotherapy Analytic psychotherapy
Confrontation therapy Confrontation therapy
Supportive counselling Supportive counselling
Aversion therapy
Hypnosis
Benzodiazepines Benzodiazepines (post-detox) for detox and beyond
Anti-depressants Anti-depressants Residential treatment
ADTRU
• Cost-effectiveness of brief alcohol interventions:
$3 to $7 return for each $1 invested
• Cost-effectiveness of treatment for alcohol dependence:
$4 to $5 return for each $1 invested
Cost-effectiveness of Treatment
for Hazardous Alcohol Use and Alcohol Dependence
ADTRU
Treatments for Alcohol Misuse: Looking to the Future
• Correspondence-based, CD-ROM and Internet therapies
• Combined CBT/motivational therapy and pharmacotherapy
• Combined pharmacotherapies
Acamprosate and naltrexone
Acamprosate and disulfiram
Naltrexone and ondansetron• Depot preparations